1 completed, 1 not yet recruiting, 1 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Jiangsu Carephar Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group, Placebo Group - Crohn's Disease | Phase 2 | Not yet recruiting | Jiangsu Carephar Pharmaceutical Co., Ltd. | 156 | 2026-07-12 | 2026-06-30 |
| A Study of Single and Multiple Ascending Doses of H021 in Healthy Participants H021, H021 Placebo - Ulcerative Colitis | Phase 1 | Unknown | Jiangsu Carephar Pharmaceutical Co., Ltd. | 64 | 2024-09-17 | 2024-10-04 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008 H008, H008 placebo, Lansoprazole - Erosive Esophagitis | Phase 1 | Completed | Jiangsu Carephar Pharmaceutical Co., Ltd. | 24 | 2021-06-24 | 2023-12-15 |
Colitis, Ulcerative (1) · Crohn Disease (1)
1-(5-(1H-indol-5-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (1) · Lansoprazole (1) · Population Groups (1)
United States (2) · Australia (1) · China (1)